Mutations in hundreds of genes involved in wiring the brain may contribute to the development of autism spectrum disorders (ASD).
That is one of the rather daunting conclusions of a paper published in the current issue of the journal Nature by a multi-institutional team that included researchers at Vanderbilt University Medical Center.
But while there is no simple explanation for ASD, the researchers identified a few genes as "genuine risk factors," raising hopes that they will be able to discover the underlying biological cause of these disorders. Numerous other genes are also strongly implicated based on their biological functions and roles in conditions related to ASD.
That knowledge could lead, in the future, to the ability to determine one's risk for developing autism and to new, more effective and personalized ways to treat individuals with an ASD, said James Sutcliffe, Ph.D., associate professor of Molecular Physiology & Biophysics and of Psychiatry at Vanderbilt, and a senior author of the paper.
Autism is a spectrum of developmental disorders characterized by impairments in communication and social interaction, and patterns of repetitive, restricted and stereotyped behaviors. According to the U.S. Centers for Disease Control and Prevention, it occurs in one in 88 children in the United States.
Researchers believe that 80 percent to 90 percent of the risk of developing ASD results from genetic factors. Despite this, only a few inherited risk factors have been discovered to date.
In the current study of 175 children with ASD and their parents, researchers in the ARRA Autism Sequencing Collaborative scoured the genome – using a technique called massively parallel sequencing – to search for mutations that might affect autism risk.
In addition to Vanderbilt, the collaborative includes researchers from Boston at the Broad Institute of MIT and Harvard and Massachusetts General Hospital, along with Baylor College of Medicine, Mount Sinai School of Medicine, the University of Pennsylvania, Carnegie Mellon University, and the University of Pittsburgh.
The researchers focused on the exome, the fraction of the human genome coding for proteins. They searched for single-letter DNA mutations that occurred spontaneously in the children and which were not present in their parents' genome.
Although rare, these so-called de novo point mutations tended to occur in genes that are functionally related to each other and to previously identified autism genes. This suggests that the proteins they encode may in some cases physically interact with each other. The relationships among the proteins encoded by these genes further supports their likely role as ASD risk factors.
With data from two other studies published in the current issue of Nature and with additional exome sequencing, the researchers identified two candidate genes. However, they explain less than 1 percent of the genetic risk of autism.
"These results clearly demonstrate the potential of DNA sequencing to articulate specific risk factors for autism," said the Broad Institute's Mark Daly, Ph.D., who, like Sutcliffe, is a senior author of the paper and a lead investigator of the ARRA Autism Sequencing Collaborative.
"We have only scratched the surface, but with continued collaborative efforts, these gene discoveries will point us to the underlying biological roots of autism."
The research described in the Nature paper was supported by ARRA (stimulus) funding from the National Institute of Mental Health and the National Human Genome Research Institute.
Bill Snyder | EurekAlert!
Selectively Reactivating Nerve Cells to Retrieve a Memory
01.06.2020 | Universität Heidelberg
CeMM study reveals how a master regulator of gene transcription operates
01.06.2020 | CeMM Forschungszentrum für Molekulare Medizin der Österreichischen Akademie der Wissenschaften
In living cells, enzymes drive biochemical metabolic processes enabling reactions to take place efficiently. It is this very ability which allows them to be used as catalysts in biotechnology, for example to create chemical products such as pharmaceutics. Researchers now identified an enzyme that, when illuminated with blue light, becomes catalytically active and initiates a reaction that was previously unknown in enzymatics. The study was published in "Nature Communications".
Enzymes: they are the central drivers for biochemical metabolic processes in every living cell, enabling reactions to take place efficiently. It is this very...
Early detection of tumors is extremely important in treating cancer. A new technique developed by researchers at the University of California, Davis offers a significant advance in using magnetic resonance imaging to pick out even very small tumors from normal tissue. The work is published May 25 in the journal Nature Nanotechnology.
researchers at the University of California, Davis offers a significant advance in using magnetic resonance imaging to pick out even very small tumors from...
Microelectronics as a key technology enables numerous innovations in the field of intelligent medical technology. The Fraunhofer Institute for Biomedical Engineering IBMT coordinates the BMBF cooperative project "I-call" realizing the first electronic system for ultrasound-based, safe and interference-resistant data transmission between implants in the human body.
When microelectronic systems are used for medical applications, they have to meet high requirements in terms of biocompatibility, reliability, energy...
Thomas Heine, Professor of Theoretical Chemistry at TU Dresden, together with his team, first predicted a topological 2D polymer in 2019. Only one year later, an international team led by Italian researchers was able to synthesize these materials and experimentally prove their topological properties. For the renowned journal Nature Materials, this was the occasion to invite Thomas Heine to a News and Views article, which was published this week. Under the title "Making 2D Topological Polymers a reality" Prof. Heine describes how his theory became a reality.
Ultrathin materials are extremely interesting as building blocks for next generation nano electronic devices, as it is much easier to make circuits and other...
Scientists took a leukocyte as the blueprint and developed a microrobot that has the size, shape and moving capabilities of a white blood cell. Simulating a blood vessel in a laboratory setting, they succeeded in magnetically navigating the ball-shaped microroller through this dynamic and dense environment. The drug-delivery vehicle withstood the simulated blood flow, pushing the developments in targeted drug delivery a step further: inside the body, there is no better access route to all tissues and organs than the circulatory system. A robot that could actually travel through this finely woven web would revolutionize the minimally-invasive treatment of illnesses.
A team of scientists from the Max Planck Institute for Intelligent Systems (MPI-IS) in Stuttgart invented a tiny microrobot that resembles a white blood cell...
19.05.2020 | Event News
07.04.2020 | Event News
06.04.2020 | Event News
29.05.2020 | Materials Sciences
29.05.2020 | Materials Sciences
29.05.2020 | Power and Electrical Engineering